FDA Fast Tracks Remlifanserin Development for Alzheimer Disease Psychosis

◆ ◆ The Wire takeaway

If you're building diagnostics or monitoring tools for Alzheimer's psychosis, a new drug entering the market means hospitals and care homes will need ways to identify and track patients eligible for treatment—that's a near-term customer acquisition window. Fast Track also signals FDA confidence in the mechanism, which de-risks clinical infrastructure suppliers and follow-on developers betting on this indication.